Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH

RegulatoryapprovedCiprocopan Succinate TabletsPositive

AI Analysis

Summary

Haisco Pharmaceutical Group announced that its Class 1 innovative drug Ciprocopan Succinate Tablets (HSK39297) has received marketing approval from China's National Medical Products Administration for the treatment of PNH. This represents a new therapeutic option for patients with paroxysmal nocturnal hemoglobinuria in the Chinese market.

Outcome Details

Class 1 innovative drug received marketing approval from the National Medical Products Administration of China

Importance:7/10

Sentiment:

0.85

China approvalPNH treatmentinnovative drugregulatory approval

Related Companies

$NHPAP $MDCE $OPTN $CHHE

Read the original article

Published by PR Newswire Pharma on July 23, 2026 6:08 AM

Read Original